Bristol-Myers Squibb Company (BMY)

Fixed asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	48,300,000	47,435,000	46,509,000	45,534,000	45,006,000	44,935,000	45,187,000	45,848,000	46,159,000	46,738,000	47,144,000	46,960,000	46,385,000	45,468,000	44,384,000	42,810,000	42,518,000	39,395,000	34,862,000	31,006,000
Property, plant and equipment	US$ in thousands	7,136,000	6,903,000	6,845,000	6,750,000	6,646,000	6,481,000	6,355,000	6,279,000	6,255,000	6,035,000	5,970,000	6,047,000	6,049,000	5,868,000	5,795,000	5,763,000	5,886,000	5,740,000	5,777,000	6,112,000
Fixed asset turnover		6.77	6.87	6.79	6.75	6.77	6.93	7.11	7.30	7.38	7.74	7.90	7.77	7.67	7.75	7.66	7.43	7.22	6.86	6.03	5.07

December 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $48,300,000K ÷ $7,136,000K
= 6.77

The fixed asset turnover ratio of Bristol-Myers Squibb Company has shown an increasing trend over the years, reflecting the company's efficient utilization of its fixed assets to generate sales. From March 31, 2020, to December 31, 2024, the ratio has steadily improved from 5.07 to 6.77.

This indicates that Bristol-Myers Squibb has been able to generate more sales in relation to its investment in fixed assets, suggesting optimal management of its capital expenditures. The peak in the ratio was observed on June 30, 2022, when it reached 7.90, showcasing a period of particularly effective asset utilization.

Although there have been minor fluctuations in the ratio over the years, the overall trend demonstrates the company's ability to efficiently leverage its fixed assets to drive revenue growth. As of December 31, 2024, the fixed asset turnover stood at 6.77, indicating that for every dollar invested in fixed assets, the company generated $6.77 in sales.